DyAnsys Inc. has embarked on the widespread commercialization of Portable ANSiscope®.
We are now shipping product into the US. After about 6 months of test marketing, it has become apparent that the sales into the chronic pain application have the highest potential. The ANSiscope is being sold as a monitor for the treatment of pain using neurostimulation. In this application it monitors the decrease of pain in the patient due to the treatment and enables the doctor to apply the treatment effectively. We are selling the monitoring and treatment package.
The next application is in diabetes. Enough research has been done (over the last 20 years) in this application, by the medical community to prove the utility and the necessity of a measurement of Autonomic Dysfunction which is a precursor to Diabetic Autonomic Neuropathy, a fatal complication of diabetes. The ADA (American Diabetes Association) has incorporated testing for autonomic neuropathy in its standards of care since Jan 2006. The product has also achieved FDA 510(K) clearance for sale in the United States. These measurements are reimbursable in the US.
There are many applications of the product in other areas of medicine since the autonomic nervous system plays a large but not well-understood role in the healthy functioning of the human body. The company expects that the availability of the product in the market will unlock many further applications. Many applications are now possible due to the beat to beat operation of the product.
The next applications we intend to focus on are anesthesia and fetal heart monitoring, where it could be used to dose analgesic drugs and to support the decision making before and during delivery. The output of the Fetal Heart Monitor has remained unchanged since it was developed in 1968. Monitoring the Fetal autonomic nervous system is what fetal heart monitoring is about and we will do this.
The ECScope Series
In the meantime, we have introduced a line of ECG machines consisting of a line of 2 products (ECScope 100 & 200). These represent "out of the box" thinking in the design of ECG machines.
We are pricing the products such that they are affordable to the medical community in every region that we operate. The usefulness and afford ability of our products will give them the potential to become fundamental medical instruments.
We are always interested in talking to potential investors who would like to be part of the growth of a medical instrumentation company with some unique technology (US patent #7, 092, 849 issued on Aug 15th, 2006) and participating in very high growth markets at very low risk. The entire technological risk is behind us.
Further investments will be used to fund the sales & marketing efforts of the company (primarily in the US) along with some investment in the development of next generation products and further new applications for ANS monitoring.
This is a unique opportunity to invest in health care company without increasing the long cycle time for health care investment. Interested parties may contact the company by email at the following address: firstname.lastname@example.org